Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.31 USD
+0.02 (5.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.30 -0.01 (-1.93%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DARE 0.31 +0.02(5.77%)
Will DARE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DARE
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
DARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
Other News for DARE
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Dare Bioscience announces it will receive payment of $1M under grant agreement
Biotech Alert: Searches spiking for these stocks today